Articles tagged with Cancer Medication
Researchers identified a critical protein for tumor cell survival and found that targeting it could be a novel treatment strategy for MSI-H tumors. The study suggests that pharmacological inhibition of WRN function might serve as a targeted therapeutic approach.
A new study finds that preventive medications, such as those for blood pressure and bone health, are frequently continued until death in older adults with cancer. The use of these medications can increase the risk of serious side effects and reduce quality of life.
A new study found that replacing a half hour of sitting time with light physical activity was associated with a nearly 50% reduction in mortality among the least active participants. Replacing sedentary time with moderate-intensity physical activity was also linked to a lower risk of death, although the association was smaller.
Researchers found that mda-7/IL-24 reduces the expression of an enzyme called DICER, which processes microRNAs for specific cellular functions. This effect occurs only in cancer cells and provides potential therapeutic targets for cancer treatment.
Researchers say gene interactions are key to understanding disease risk and treatment response, but current methods lack statistical power to uncover multiple genes. Genome-wide association studies have identified thousands of mutations that contribute to disease, but environmental effects and genetic diversity complicate matters.
Researchers have found that modulating blood-forming stem cells' stiffness could help drive them out of the bone marrow and into the blood, but they need to be stiff to stay put. The study, published in Cell Stem Cell, suggests that altering cell biomechanics can improve mobilization regimens for stem cell-based therapy.
Researchers at City of Hope have been awarded $7.5 million to develop new treatments for CTCL, a disfiguring and incurable cancer affecting about 3,000 individuals annually. The grant will support the development of personalized medicine and immunotherapy treatments.
The collaboration identifies leadership, patient engagement, and community engagement as crucial factors in increasing accrual of racial and ethnic minorities in cancer trials. High-recruiting centers like Henry Ford Cancer Institute excel in engaging providers, building trust, and seeking input from minority patients and caregivers.
Researchers found that cancer cells with fewer mitochondria are more likely to respond to certain drug treatments, offering a new avenue for targeted therapies. The study's findings suggest that enhancing understanding of the relationship between mitochondrial variability and drug response may lead to more effective cancer treatments.
Researchers at Oregon State University have patented a method for synthesizing cephalotaxine and homoharringtonine (HHT), previously only available from an Asian tree. This development paves the way for more readily available and affordable leukemia treatments.
Researchers have identified a promising new therapeutic strategy using two types of drug inhibitors to treat pancreatic cancer. The approach combines chloroquine with an inhibitor of the replication stress response pathway, showing potential in reducing tumor growth and improving prognosis.
Researchers at University of Alabama at Birmingham discovered androgen receptor imports into mitochondria, where it regulates multiple mitochondrial processes. This finding may lead to new treatment targets for castration-resistant prostate cancer.
Scientists at the University of Wisconsin-Madison have discovered an unexpected regulator of the p53 protein, which plays a crucial role in cancer development. The research team found that an enzyme called PIPK1-alpha and its lipid messenger, PIP2, drive the stability of mutant p53, leading to cancer progression.
Research has led to increased understanding of genetic changes in cancer, highlighting the potential for personalized care in children with cancer. Genetic profiling can inform prognosis and treatment decisions, providing critical information about tumor progression and response.
Researchers at Stanford University School of Medicine have discovered a method to forecast which breast cancer patients will experience heart problems from trastuzumab, a commonly used chemotherapy drug. A class of medications already approved by the FDA may mitigate these side effects.
A new study shows that innovative communication programs can improve patients' mental health symptoms and quality of life. The program, which involves structured conversations between clinicians and patients, results in more timely and meaningful discussions about patient values and goals.
A study from MIT and Brigham and Women's Hospital found that nearly all pills and capsules contain ingredients that can cause allergic reactions or irritations in certain patients. The researchers aim to raise awareness of this issue and stimulate reforms to protect patients.
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a distinct form of cancer linked to textured breast implants. Clear guidelines formalize treatment strategy, recommending surgical techniques like stepwise en bloc resection for complete oncologic resection and removal of involved lymph nodes.
A nationally representative study found that teenagers and young adults are more likely to use fruit- and candy-flavored e-cigarettes than their adult counterparts. The study also revealed that adolescent vapers were more likely to experiment with multiple flavor types, which may be a key factor in their vaping habits.
A new experimental drug, 673A, targets and annihilates stem-like ovarian cancer cells that cause recurrence. The treatment, combined with chemotherapy, resulted in significantly greater survival rates in a mouse model of ovarian cancer.
A team of scientists has discovered a unique genetic signature, or 'fingerprint', in cancer cells that can be targeted to selectively eliminate abnormal cells. This breakthrough could lead to more effective and less toxic cancer treatments.
PARP inhibitors have been found to enhance the immune response against cancer cells with DNA repair defects, suggesting a new approach to treating various types of cancer. This discovery could lead to increased effectiveness of immunotherapies and improved treatment outcomes for patients.
A study found that rural areas have higher levels of ambiguity and fatalism regarding cancer, which can discourage participation in screenings. Researchers hope to develop customized interventions based on community needs and values.
Researchers have discovered a potential treatment for cancer in patients with epidermolysis bullosa, a severe skin disease also known as butterfly disease. The new drug, rigosertib, was shown to be highly effective at killing cancer cells in preclinical studies and may target the cancer without harming healthy cells.
Researchers at Bar-Ilan University discovered the intricate molecular mechanism of the guidance receptor 'Robo', which reacts to signals in its environment while avoiding premature activity. The findings provide a basis for designing effective drugs targeting Robo receptors, potentially treating various neurological and cancer conditions.
Researchers at University of Tsukuba uncover how stratifin causes lung adenocarcinoma to emerge, identifying two drugs with other clinical uses that could be applied effectively in this disease. The study's findings raise hopes for more powerful treatment tools and value drug repositioning as a potential solution.
Researchers have found a pair of old drugs that can disrupt disease-causing pathways in triple negative breast cancer. Metformin and heme, previously used to treat diabetes and porphyria, were tested in mice and produced encouraging results when combined.
Researchers at The Wistar Institute have developed a drug candidate for EBV-associated cancers, inhibiting tumor growth in preclinical models. Pharmacological inhibition of EBNA1 had profound effects on gene expression, decreasing EBV DNA copy number and suppressing tumor-promoting pathways.
Researchers created metallocorrole/protein nanoparticles that can both survive longer in the body and better snipe disease targets. The theranostics have huge chemotherapeutic potential, potentially shortening treatment duration and diminishing side effects for cancer patients.
A new study by Boston University School of Public Health evaluates the Novartis Access program in Kenya, demonstrating that robust, 'gold standard' methods can be used to assess major pharmaceutical companies' access programs. The study found that the program significantly increased availability of two medicines in health facilities bu...
UC San Diego Health, Ochsner Health System, Sutter Health and Stanford Health Care developed diverse models of care incorporating patient-centered technologies with measurable outcomes. Technology improved medication adherence for hypertension and diabetes, reduced distress in cancer patients, and enhanced patient engagement.
Researchers identified S15 as a major immune suppressor in B7-H1-negative tumors resistant to current anti-PD therapies. A first-in-human Phase 1/2 clinical trial is underway for NC318, a monoclonal antibody targeting S15.
Despite the risks, many health care workers do not use recommended personal protective equipment when handling chemotherapy. A study from Michigan Medicine found that nurses who reported handling hazardous drugs had twice the risk of reproductive problems.
Ugur Sahin received the 2019 German Cancer Award for his pioneering research on individualized cancer immunotherapies. He is developing technologies to identify and exploit unique cancer characteristics to guide the immune system against specific tumors.
Researchers found that lung cancer cells acquire resistance to molecular-targeted drugs by transforming epithelial characteristics into mesenchymal ones, leading to reduced miR-200c expression. Sequential treatment with an HDAC inhibitor and a next generation molecular-targeted drug overcomes this resistance, offering new potential for...
Researchers at U of T Engineering created a 3D hydrogel to mimic lung cancer environments, selectively allowing cancer cells to invade. This technology enables rapid screening of hundreds of potential drugs for their ability to fight invasive cancers.
Researchers at UCLA have developed a method to screen hundreds of drugs in patients' own cells, creating miniature tumor organoids. This approach can help identify effective treatments for rare and hard-to-treat cancers, and could guide treatment decisions.
Cancer stem-cells are responsible for recurrence and drug resistance. MTHFD2, a mitochondrial metabolic enzyme, plays a critical role in maintaining CSCs by consuming AICAR, leading to depletion of the intracellular pool. Targeting MTHFD2 may eradicate tumors and prevent recurrence.
A clinical trial found sacituzumab govitecan produced a significant treatment response in patients with difficult-to-treat metastatic triple-negative breast cancer, outperforming standard chemotherapy. The drug showed manageable side effects and improved treatment duration.
A new 'smart drug', sacituzumab govitecan, has shown significant tumor shrinkage and improved patient outcomes in a clinical trial for women with metastatic triple-negative breast cancer. The treatment resulted in better response rates and longer overall survival compared to traditional therapies.
Researchers at Johns Hopkins Medicine have discovered a new compound called rapadocin that may prevent reperfusion injury, a tissue-damaging complication of surgery. The compound was found to block the activity of a chemical pathway associated with reperfusion injuries, reducing markers of kidney damage in mice.
The Mark Foundation has selected 14 new ASPIRE Award winners, funding high-risk, high-reward cancer research projects across the US and internationally. These projects focus on early cancer detection, immunotherapy, tumor microenvironment, and more, with the potential to advance cancer medicine.
A study by Cedars-Sinai Medical Center has identified a drug called dasatinib that could enhance the effectiveness of immunotherapies for various types of cancers. The researchers found that combining dasatinib with anti-PD-1 therapy increased sensitivity in cancer cells, making it a promising approach to improve treatment outcomes.
Researchers from the University of Sheffield discovered a compound that kills cancer cells without triggering apoptosis, making it resistant to treatment. The new drug lead is highly active against treatment-resistant cancers and may be particularly effective against ovarian cancer.
Researchers at CNIC identified a very early marker of cardiac damage in patients undergoing anthracycline therapy, allowing for early diagnosis and potential prevention of irreversible damage. The discovery has implications for patient prognosis and may lead to new therapies based on mitochondrial transplantation.
A phase 3 clinical trial found that a combination of two drugs, including an immunotherapy agent, significantly improved progression-free survival and response rates compared to a standard treatment. The results suggest that the new treatment may become a new standard for first-line treatment for patients with metastatic kidney cancer.
The open-science model is being expanded to neurodegenerative diseases such as Parkinson's and Amyotrophic Lateral Sclerosis. M4ND Pharma will pursue promising new genetic drug targets, sharing progress with the scientific community through regular online meetings.
Researchers are studying animal venoms to identify molecular targets for diseases such as osteoarthritis, rheumatoid arthritis, cancer, and neurodegenerative diseases. The study found promising antitumoral effects and potential new compounds that can be used as medicines.
A recent study published by The Endocrine Society found that oral complications are rare in women taking medications for postmenopausal osteoporosis. Despite concerns among dentists and patients, the rate of osteonecrosis of the jaw (ONJ) was low, with only 5.2 cases per 10,000 patient-years reported.
A new therapeutic target has been identified for aggressive pediatric cancers with few treatment options. The researchers discovered that malignant rhabdoid tumors may be sensitive to drugs that block the cancer cell's ability to dispose of misfolded proteins, and a Phase II clinical trial is underway to investigate this approach.
Researchers create 3D in vitro model capable of isolating specific metastatic cells, providing platform for identifying potential therapies and screening anticancer drugs. The model also enables study of interactions between vasculature and drugs, yielding important answers.
A UCLA-led study found that administering immunotherapy drug pembrolizumab before surgery significantly extended the lives of people with recurrent glioblastoma. The study showed that those who received the drug prior to surgery lived nearly twice as long after surgery compared to those who received it afterward.
Researchers at Karolinska Institutet develop new approach to targeted cancer treatment using Class Frizzled receptors, potentially effective against rectal and lung cancers. The study reveals molecular details of receptor activation and pathway selection.
A new cancer drug called tisotumab vedotin has shown significant promise in treating various types of cancer, with a response rate of up to 27% in patients with advanced, drug-resistant cancers. The treatment works by releasing a toxic substance to kill cancer cells from within and has manageable side effects.
Researchers at Scripps Research Institute have developed a new approach to shifting breast cancer cells into HER2-positive status using RNA-targeting precision medicines. The proof-of-concept study suggests that this technology could expand treatment options for patients with dwindling choices.
A study of 2,766 physicians found that those receiving payments from a cancer drug's manufacturer were more likely to prescribe the drug for certain types of cancer, including kidney and lung cancer. Financial relationships between physicians and drug companies can influence prescribing practices.
A multi-pronged effort will be launched to combat cervical cancer in Malawi, with a focus on early screening and same-day treatment of precancerous lesions using thermocoagulation. The project aims to increase the number of women screened and treated, and decrease loss to follow up.
A new study has identified a pair of genes that can mimic the effects of BRCA proteins, potentially making tumor cells susceptible to PARP inhibitors. The researchers found that targeting these genes could improve treatment options for people with breast or ovarian cancer caused by BRCA defects.
Researchers discovered how a metallodrug reaches cancer cells and attacks them efficiently. The molecule penetrates the cell membrane and targets essential organelles, leading to anticancer activity.
Cancer researchers have mapped oesophageal adenocarcinoma genes in unprecedented detail, unveiling more than half as potentially targetable by drugs already in trials for other cancers. This breakthrough could lead to personalized therapies and improved treatment options for patients.